No price history available for this symbol yet.
Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Sector
Medical - Instruments & Supplies
Austco Healthcare Limited, through its subsidiaries, operates as a global entity focused on the development, production, and comprehensive servicing of advanced healthcare and electronic communication systems. The company's market reach extends across Australia, New Zealand, Asia, Europe, and North America. A significant product in its portfolio is Tacera, an internet protocol (IP) based nurse call solution specifically engineered for both hospitals and aged care facilities. Originally founded in 1986, the company adopted its current name, Austco Healthcare Limited, in November 2020, having previously been known as Azure Healthcare Limited. Its corporate headquarters are located in Port Melbourne, Australia.
austcohealthcare.comNo one on the platform currently holds AHC.AX.
No tracked institution reports a position in AHC.AX as of their last filing.
No one on the platform has traded AHC.AX yet.
Consensus-seeded revenue, margins, and exit multiples. This is a scenario tool, not investment advice.
Consensus does not cover every selected forecast year. Later assumptions are extrapolated from available analyst estimates.
| Metric | Historical average | My assumptions | ||||
|---|---|---|---|---|---|---|
| 1 year | 5 years | 10 years | Low | Mid | High | |
| ROIC % | 16.9% | 15.8% | — | — | — | |
| Rev. Growth % | 15.8% | 24.7% | ||||
| Profit Margin % | 9.6% | 8.2% | 4.4% | |||
| Free Cash Flow Margin % | 12.4% | 7.2% | 4.7% | |||
| Exit P/E | — | — | — | |||
| Exit P/FCF | — | — | — | |||
| Desired Annual Return % | — | — | — | |||
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
| Year | Est. revenue | Growth | Est. EPS | EPS range | Fwd P/E | # Analysts |
|---|---|---|---|---|---|---|
| 2027 | $102M | +8.5% | $0.03 | $0.03–$0.03 | — | 1 |
| 2028 | $109M | +7.1% | $0.03 | $0.03–$0.03 | — | 2 |
| 2029 | $117M | +7.0% | $0.03 | $0.03–$0.03 | — | 1 |
Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep
| -2.94% |
| $145M |
| — |
| PAR.AXParadigm Biopharmaceuticals Limited | $0.25 | +4.17% | $150M | — |
| PEB.AXPacific Edge Limited | $0.21 | +0.00% | $261M | — |
Source: Financial Modeling Prep · peers by sector/industry